Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 10 mg

Retatrutide (10 mg Vial)

Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses. This educational protocol presents a once-weekly subcutaneous approach with gradual titration to minimize gastrointestinal side effects.

Detailed protocol below.

Dosing Schedule
PhaseWeekly DoseUnits (per injection) (mL)Vials Needed
Weeks 1–42 mg (2000 mcg)20 units (0.20 mL)1 vial per dose
Weeks 5–84 mg (4000 mcg)40 units (0.40 mL)1 vial per dose
Weeks 9–126 mg (6000 mcg)60 units (0.60 mL)1 vial per dose
Weeks 13+8 mg (8000 mcg)80 units (0.80 mL)1 vial per dose
Supplies Needed
  • •Peptide Vials (Retatrutide, 10 mg each):
  • •Insulin Syringes (U-100, 1 mL capacity):
  • •Bacteriostatic Water (10 mL bottles): Use ~1.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for each injection site.
References

  • The Lancet (2023)

    Rosenstock J, et al. Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss)

    View source

  • New England Journal of Medicine (2023)

    Jastreboff AM, et al. Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss)

    View source

  • American Diabetes Association (2023)

    ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data)

    View source

  • ADA Meeting News (2023)

    Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage)

    View source

  • ClinicalTrials.gov

    Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760; protocol details, dosing regimens)

    View source

  • Current Obesity Reports (2025)

    Hamza M, et al. Triple agonism based therapies for obesity (review; titration strategies, GI side effect management)

    View source

  • Cell Metabolism (2022)

    Coskun T, et al. LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism)

    View source

  • Diabetes Care (2024)

    Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure)

    View source

  • NEJM (2023) — Supplementary Material

    Supplementary Material**

    View source

  • Hepatology (2024)

    Triple agonists in NAFLD/NASH: hepatic steatosis resolution (preclinical and clinical evidence)

    View source

  • The Lancet (2023) — Supplementary Data

    Supplementary Data**

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site guidance; no aspiration required)

    View source

  • Johns Hopkins Arthritis Center

    How to give a subcutaneous injection (technique, site rotation, sharps disposal)

    View source

  • NCBI Bookshelf

    Administration of medication: subcutaneous injections (aseptic technique, preparation)

    View source

  • GenScript Peptide Services

    Peptide storage and handling guidelines (lyophilized and reconstituted storage conditions, stability)

    View source

  • Journal of Pharmaceutical Sciences (2018)

    Stability of peptides during freeze-thaw cycles (best practices for aliquoting and storage)

    View source

Educational content adapted from peptidedosages.com. Not medical advice.